Tenaya Therapeutics (TNYA)
US Market

Tenaya Therapeutics (TNYA) Stock Price & Analysis


TNYA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.64 - $16.17
Previous Close$3.42
Average Volume (3M)322.39K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$149.45M
Total Debt (Recent Filing)$16.06M
Price to Earnings (P/E)-1.2
Next EarningsMar 22, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.81
Shares Outstanding63,987,996
Standard Deviation0.19
10 Day Avg. Volume281,741
30 Day Avg. Volume322,386
Price to Book (P/B)0.83
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside508.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $1.64 and its highest was $16.17 in the past 12 months.
    What is Tenaya Therapeutics’s market cap?
    Currently, no data Available
    When is Tenaya Therapeutics’s upcoming earnings report date?
    Tenaya Therapeutics’s upcoming earnings report date is Mar 22, 2023 which is in 53 days.
      How were Tenaya Therapeutics’s earnings last quarter?
      Tenaya Therapeutics released its earnings results on Nov 10, 2022. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.655 by -$0.085.
        Is Tenaya Therapeutics overvalued?
        According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Tenaya Therapeutics pay dividends?
          Tenaya Therapeutics does not currently pay dividends.
          What is Tenaya Therapeutics’s EPS estimate?
          Tenaya Therapeutics’s EPS estimate is -$0.63.
            How many shares outstanding does Tenaya Therapeutics have?
            Tenaya Therapeutics has 63,987,995 shares outstanding.
              What happened to Tenaya Therapeutics’s price movement after its last earnings report?
              Tenaya Therapeutics reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.655. Following the earnings report the stock price went up 30.882%.
                Which hedge fund is a major shareholder of Tenaya Therapeutics?
                Among the largest hedge funds holding Tenaya Therapeutics’s share is RA Capital Management. It holds Tenaya Therapeutics’s shares valued at 5M.


                  Tenaya Therapeutics Stock Smart Score

                  The Tenaya Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Tenaya Therapeutics

                  Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Avita Medical
                  Merrimack Pharmaceuticals
                  W World

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis